Cell and Gene Commercialization

  1. Exciting Areas Of Innovation For Cell Therapies 12/23/2024

    In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.

  2. Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond 12/17/2024

    In this executive roundtable discussion, Bioprocess Online editor Tyler Menichiello is joined by CEO, co-founder, and president of Ossium Health, Kevin Caldwell, CSO of FibroBiologics, Hamid Khoja, Ph.D., and president and acting CEO of Triumvira Immunologics, Rob Williamson. The panelists share their predictions and thoughts on the industry’s direction heading into 2025. They cover manufacturing trends (noting opportunities for improvements in cell therapy manufacturing), AI adoption, regulatory concerns, and the potentially challenging funding environment ahead. 

  3. Expand The Use And Value Of Your Product Over Time 12/2/2024

    This discussion explores a forward-thinking approach that encourages biotech companies to look beyond initial approval, exploring new indications, markets, and patient populations.

  4. Implement Market Launch Strategy, Pre-Approval 12/2/2024

    By focusing on proactive planning and risk mitigation, this episode offers biotech leaders actionable insights to optimize their pre-launch strategies, setting the stage for a strong market debut and sustained commercial success.

  5. Plan How To Get To Market Quickly, Post Proof-Of-Concept 12/2/2024

    This episode of the De-risking Drug Development series focuses on accelerating drug development and enhancing product differentiation through innovative trial design.

  6. Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases 11/26/2024

    EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.

  7. RNA Therapeutics: New Market Research 11/14/2024

    According to our new market research, the RNA therapeutics industry is predicted to exceed $31 billion by 2032. This article shares key findings and trends.

  8. Leveraging Platform And Process Characterization Data To Accelerate CGT Validation And Commercialization 11/12/2024

    Accelerate the delivery of cell and gene therapies by adopting streamlined validation and leveraging strategies that reduce timelines and support sustainable, compliant manufacturing pipelines.

  9. Perspectives On Performance, Scalability, And Regulatory Compliance 10/28/2024

    Here, we discuss the challenges and solutions for cell and gene therapies, focusing on performance, scalability, and regulatory compliance to accelerate commercialization and improve patient access.

  10. Highlights From ARM's 2024 Meeting On The Mesa 10/25/2024

    ARM's 2024 Meeting on the Mesa has concluded. Here are a few brief highlights from this year's conference.